Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Mol Cancer Res. 2018 May 14;16(8):1226–1240. doi: 10.1158/1541-7786.MCR-17-0406

Figure 1. Guadecitabine treatment of adipocytes decreases migration and invasion of epithelial ovarian cancer cells.

Figure 1

(A). OVCAR5, OVCAR4, OVCAR8, Kuramochi, and SKOV3 cells (200,000) were seeded in the top of the Boyden chamber and allowed to migrate (8h) or (B) invade (16h) towards adipocytes in a 24-well plate. (C). Adipocytes were treated with guadecitabine (100nM, daily 3X), removed and replaced with serum-free media; then ovarian cancer cells (200,000) were seeded in the top of the Boyden chamber and allowed to migrate (8h) or (D) invade (16h). (E). Adipocyte-conditioned media (ACM) collected from adipocytes treated with guadecitabine (100nM, daily 3X) or blank media was used to culture OVCAR8 and (F) OVCAR4 cells for 24h. EMT markers (SLUG, FN1, TWIST1, CDH1, CDH2, VIM, ITGB1) were analyzed by qRT-PCR with RNA from OVCAR8 and OVCAR4 cells. All experiments were performed in triplicate. (*P < 0.05, **P < 0.01).